Literature DB >> 26561389

Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis.

Jason M Warfel1, Lindsey I Zimmerman1, Tod J Merkel2.   

Abstract

Pertussis is a highly contagious respiratory illness caused by the bacterial pathogen Bordetella pertussis. Pertussis rates in the United States have escalated since the 1990s and reached a 50-year high of 48,000 cases in 2012. While this pertussis resurgence is not completely understood, we previously showed that the current acellular pertussis vaccines do not prevent colonization or transmission following challenge. In contrast, a whole-cell pertussis vaccine accelerated the rate of clearance compared to rates in unvaccinated animals and animals treated with the acellular vaccine. In order to understand if these results are generalizable, we used our baboon model to compare immunity from whole-cell vaccines from three different manufacturers that are approved outside the United States. We found that, compared to clearance rates with no vaccine and with an acellular pertussis vaccine, immunization with any of the three whole-cell vaccines significantly accelerated the clearance of B. pertussis following challenge. Whole-cell vaccination also significantly reduced the total nasopharyngeal B. pertussis burden, suggesting that these vaccines reduce the opportunity for pertussis transmission. Meanwhile, there was no difference in either the duration or in B. pertussis burden between unvaccinated and acellular-pertussis-vaccinated animals, while previously infected animals were not colonized following reinfection. We also determined that transcription of the gene encoding interleukin-17 (IL-17) was increased in whole-cell-vaccinated and previously infected animals but not in acellular-pertussis-vaccinated animals following challenge. Together with our previous findings, these data are consistent with a role for Th17 responses in the clearance of B. pertussis infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26561389      PMCID: PMC4711092          DOI: 10.1128/CVI.00449-15

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  29 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.

Authors:  Rose-Minke Schure; Lotte H Hendrikx; Lia G H de Rond; Kemal Oztürk; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  Clin Vaccine Immunol       Date:  2013-07-03

3.  A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.

Authors:  K Stehr; J D Cherry; U Heininger; S Schmitt-Grohé; M uberall; S Laussucq; T Eckhardt; M Meyer; R Engelhardt; P Christenson
Journal:  Pediatrics       Date:  1998-01       Impact factor: 7.124

Review 4.  Possible options for new pertussis vaccines.

Authors:  Bruce D Meade; Stanley A Plotkin; Camille Locht
Journal:  J Infect Dis       Date:  2014-04-01       Impact factor: 5.226

Review 5.  The baboon model of pertussis: effective use and lessons for pertussis vaccines.

Authors:  Jason M Warfel; Tod J Merkel
Journal:  Expert Rev Vaccines       Date:  2014-09-03       Impact factor: 5.217

Review 6.  Re-emergence of pertussis: what are the solutions?

Authors:  Romina Libster; Kathryn M Edwards
Journal:  Expert Rev Vaccines       Date:  2012-11       Impact factor: 5.217

7.  A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.

Authors:  F Simondon; M P Preziosi; A Yam; C T Kane; L Chabirand; I Iteman; G Sanden; S Mboup; A Hoffenbach; K Knudsen; N Guiso; S Wassilak; M Cadoz
Journal:  Vaccine       Date:  1997-10       Impact factor: 3.641

8.  Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model.

Authors:  Jason M Warfel; Lindsey I Zimmerman; Tod J Merkel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

9.  Complete Genome Sequence of Bordetella pertussis D420.

Authors:  Christine J Boinett; Simon R Harris; Gemma C Langridge; Elizabeth A Trainor; Tod J Merkel; Julian Parkhill
Journal:  Genome Announc       Date:  2015-06-11

10.  Notice to readers: final 2012 reports of nationally notifiable infectious diseases.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-08-23       Impact factor: 17.586

View more
  23 in total

Review 1.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

2.  Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.

Authors:  Ricardo da Silva Antunes; Mariana Babor; Chelsea Carpenter; Natalie Khalil; Mario Cortese; Alexander J Mentzer; Grégory Seumois; Christopher D Petro; Lisa A Purcell; Pandurangan Vijayanand; Shane Crotty; Bali Pulendran; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

3.  Vaccine-driven virulence evolution: consequences of unbalanced reductions in mortality and transmission and implications for pertussis vaccines.

Authors:  Ian F Miller; C Jessica Metcalf
Journal:  J R Soc Interface       Date:  2019-12-11       Impact factor: 4.118

4.  Toward a Controlled Human Infection Model of Pertussis.

Authors:  Tod J Merkel
Journal:  Clin Infect Dis       Date:  2020-07-11       Impact factor: 9.079

Review 5.  Pertussis vaccines and protective immunity.

Authors:  Parul Kapil; Tod J Merkel
Journal:  Curr Opin Immunol       Date:  2019-05-09       Impact factor: 7.486

6.  Use of a Toxin Neutralization Assay To Characterize the Serologic Response to Adenylate Cyclase Toxin after Infection with Bordetella pertussis.

Authors:  Joshua C Eby; Mary C Gray; Jason M Warfel; Tod J Merkel; Erik L Hewlett
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

7.  Histopathology of Bordetella pertussis in the Baboon Model.

Authors:  Lindsey I Zimmerman; James F Papin; Jason Warfel; Roman F Wolf; Stanley D Kosanke; Tod J Merkel
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

8.  Estimating Population-Level Effects of the Acellular Pertussis Vaccine Using Routinely Collected Immunization Data.

Authors:  Madhura S Rane; M Elizabeth Halloran
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 9.079

9.  Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.

Authors:  Fouzia Farooq; Kevin Beck; Kristopher M Paolino; Revell Phillips; Norman C Waters; Jason A Regules; Elke S Bergmann-Leitner
Journal:  Sci Rep       Date:  2016-06-21       Impact factor: 4.379

Review 10.  The immunological mechanisms that control pneumococcal carriage.

Authors:  Simon P Jochems; Jeffrey N Weiser; Richard Malley; Daniela M Ferreira
Journal:  PLoS Pathog       Date:  2017-12-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.